Curaleaf has officially launched a hostile takeover attempt for Aurora Cannabis, bypassing the company’s board of directors to appeal directly to shareholders with an unsolicited bid valued at approximately 272 million US dollars. The move comes after Connecticut based Curaleaf claims that repeated attempts to negotiate privately were ignored or rebuffed by Aurora leadership. To entice investors, Curaleaf is offering an implied value of 4 dollars per share, consisting of a mix of cash and stock, which represents a substantial premium over Aurora’s recent trading average.
The tension between the two companies has already spilled into a public war of words. Curaleaf CEO Boris Jordan expressed disappointment that the Aurora board refused to engage meaningfully despite several formal letters of intent sent throughout June and July. On the other hand, Aurora has pushed back against this characterization, suggesting that Curaleaf’s initial proposals lacked sufficient detail regarding financial terms. While admitting they received the offers, Aurora noted that their current focus remains on executing their own internal business plan, though they have formed a special committee of independent directors to evaluate whether the deal serves the best interests of their stakeholders.
If the acquisition were to succeed, it would create one of the most formidable players in the global cannabis industry. The combined entity would operate across 17 different countries with a market capitalization nearing 3 billion US dollars. Beyond just scale, Curaleaf is eyeing Aurora’s impressive European footprint, specifically its high standard cultivation and manufacturing capacity through assets like the Safari Flower Company. This infrastructure would provide Curaleaf with an immediate springboard into more regulated international markets.
Market reaction was swift following the announcement, sending Aurora shares climbing more than 20 percent on Tuesday. For Aurora investors, the bid provides a potential lifeline after a volatile twelve month period where share prices struggled despite modest revenue growth. As both sides dig in their heels, shareholders now find themselves at the center of a corporate tug of war that could fundamentally reshape the landscape of North American and European cannabis production.
